SUTRO BIOPHARMA, INC. Quarterly Operating Income (Loss) in USD from Q3 2017 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Sutro Biopharma, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q3 2017 to Q2 2024.
  • Sutro Biopharma, Inc. Operating Income (Loss) for the quarter ending June 30, 2024 was -$48.7M, a 5.43% decline year-over-year.
  • Sutro Biopharma, Inc. Operating Income (Loss) for the twelve months ending June 30, 2024 was -$106M, a 33.2% increase year-over-year.
  • Sutro Biopharma, Inc. annual Operating Income (Loss) for 2023 was -$89.3M, a 30.8% increase from 2022.
  • Sutro Biopharma, Inc. annual Operating Income (Loss) for 2022 was -$129M, a 30.9% decline from 2021.
  • Sutro Biopharma, Inc. annual Operating Income (Loss) for 2021 was -$98.5M, a 38.7% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 -$106M -$48.7M -$2.51M -5.43% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-13
Q1 2024 -$104M -$56.6M -$14.4M -34% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-13
Q4 2023 -$89.3M $43.2M +$92.4M Oct 1, 2023 Dec 31, 2023 10-K 2024-03-25
Q3 2023 -$182M -$44M -$22.8M -108% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-13
Q2 2023 -$159M -$46.2M -$26.8M -138% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-13
Q1 2023 -$132M -$42.2M -$3.11M -7.94% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-13
Q4 2022 -$129M -$49.2M -$14.2M -40.5% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-25
Q3 2022 -$115M -$21.2M +$13.5M +38.8% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-13
Q2 2022 -$128M -$19.4M -$9.57M -97.6% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-10
Q1 2022 -$119M -$39.1M -$20.1M -106% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-15
Q4 2021 -$98.5M -$35M -$10.2M -41% Oct 1, 2021 Dec 31, 2021 10-K 2024-03-25
Q3 2021 -$88.3M -$34.7M -$24.1M -227% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-08
Q2 2021 -$64.3M -$9.81M +$6.61M +40.3% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-08
Q1 2021 -$70.9M -$19M +$171K +0.89% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-09
Q4 2020 -$71.1M -$24.8M -$10.1M -68.1% Oct 1, 2020 Dec 31, 2020 10-K 2023-03-30
Q3 2020 -$61M -$10.6M +$2.12M +16.6% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-10
Q2 2020 -$63.1M -$16.4M -$2.73M -20% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-09
Q1 2020 -$60.4M -$19.2M -$4.91M -34.4% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-07
Q4 2019 -$55.5M -$14.8M -$11.5M -351% Oct 1, 2019 Dec 31, 2019 10-K 2022-02-28
Q3 2019 -$44M -$12.7M -$2.58M -25.4% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-05
Q2 2019 -$41.4M -$13.7M -$1.6M -13.2% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-06
Q1 2019 -$39.8M -$14.3M -$2.56M -21.9% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-11
Q4 2018 -$37.2M -$3.28M Oct 1, 2018 Dec 31, 2018 10-K 2021-03-18
Q3 2018 -$10.2M -$9.09M -854% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-08
Q2 2018 -$12.1M Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-14
Q1 2018 -$11.7M Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-15
Q3 2017 -$1.07M Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.